NEW YORK -- Just days after selling her ImClone Systems stock, Martha Stewart said she knew that ImClone CEO Sam Waksal had been trying to dump his shares in the company, a close friend of Stewart testified yesterday.
The revelation by Mariana Pasternak, a friend of Stewart for more than 20 years, was perhaps the most damaging testimony yet against Stewart, who claims she sold the stock for an entirely different reason.
Pasternak said Stewart told her about the Waksal sale on Dec. 30, 2001, just three days after Stewart sold her 3,928 shares of ImClone. The pair were on a terrace at a Mexican resort where they were vacationing.
Pasternak said Stewart recalled Waksal "was selling or trying to sell his stock, that his daughter was selling or trying to sell . . . " She said Stewart added: "Isn't it nice to have brokers who tell you those things?"
What Stewart knew about Waksal when she sold her stock goes to the heart of the government's case that she repeatedly lied to investigators in the ImClone probe.
Stewart told investigators she never recalled being tipped that Waksal was selling, and that she sold instead because she and her stockbroker had a prearranged agreement to sell Stewart's ImClone shares at a certain price.
Earlier yesterday, a forensics expert testified that broker Peter Bacanovic had used a different ink to make a notation next to an entry for ImClone Systems stock on a worksheet of Stewart's stock sales.
The government contends Bacanovic made the notation after he and Stewart hatched the false $60 story.
The chief forensic scientist at the US Secret Service, Larry Stewart, who is considered the nation's top expert on ink, said infrared and ultraviolet light tests had confirmed differences between the "(at)60" entry and other marks on the sheet.
"The `(at)60' entry is a different ink than the remaining entries on the document," said the forensic scientist, who is no relation to Martha Stewart.
The worksheet, among the most critical pieces of government evidence in the trial, is a summary of gains and losses in 36 stocks Stewart owned in late 2001 at Merrill Lynch & Co.
Bacanovic made circles, check marks, and other notations in blue ink on the document. The "(at)60" mark, also in blue ink, is underlined and appears next to an entry for Stewart's 3,928 shares of ImClone.
Under cross-examination, the ink expert said it was impossible to tell how many pens had been used to mark on the document.
Bacanovic claims he and Stewart struck the $60 agreement days before she sold her stock on Dec. 27, 2001. The next day, the government declined to review an ImClone cancer-fighting drug, sending the stock price into a sharp decline.
Larry Stewart testified that ultraviolet-light and chromatography testing had confirmed the inks were distinct. The document was tested in July and August 2002 and was retested in January of this year.Martha Stewart's lawyer, Robert Morvillo, indicated to the judge yesterday that he still had not decided whether his client will take the witness stand. Morvillo planned to ask the judge to dismiss the securities fraud count against Stewart, which charges her with misleading investors in her company, Martha Stewart Living Omnimedia, by claiming her ImClone sale had been proper.
Outside the jury's presence yesterday, US District Judge Miriam Goldman Cedarbaum blocked the government from showing jurors that Stewart haggled over reimbursements from her company for haircuts and other minor expenses.
Prosecutors wanted to raise the issue to head off assertions by Morvillo that Stewart would not have focused closely on her sale of ImClone Systems stock.